Subject:
Medications
Short Description:
Fetzima Approved for Depression
Background:
In July 2013, the FDA approved the SNRI Fetzima (levomilnacipran) for major depressive disorder (MDD) in adults (Forest Laboratories, Inc). The efficacy of Fetzima at doses 40 mg to 120 mg once daily was established in three, eight-week, randomized, double-blind, placebo-controlled studies in adults diagnosed MDD.
Levomilnacipran is an active enantiomer of milnacipran, the active ingredient in the SNRI Savella, which is approved for the treatment of fibromyalgia. However, Fetzima is not approved for fibromyalgia and Savella is not approved for depression.
Common side effects include nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2024 Carlat Publishing, LLC and Affiliates, All Rights Reserved.